Tarsons Products Limited

TARSONS NSE Healthcare Medical Equipment & Supplies
₹311.20
-2.03%
Delayed · cached 15 min

Fair value analysis

TARSONS
Tarsons Products Limited
HealthcareMedical Equipment & Supplies
₹317.65
Close used for this calculation
₹182.21Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
18/100
Profitability4/25
Returns6/25
Balance Sheet6/25
Efficiency2/25
Growth0/25
Weak
Quality radar
18Prof.4/25Ret.6/25Eff.2/25B.Sht6/25Growth0/25

Consensus fair value

₹182.21
Above FV
▼ -42.6% against the close used
Model range ₹24.53 – ₹337.02
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹24.53Fair value₹182.21Bull₹337.02
FairClose
52-week traded range
52W low ₹166.4652W high ₹361.50

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Tarsons Products Limited closed at ₹317.65, 74.3% above the consensus fair value of ₹182.21 drawn from 7 valuation models.

Financial DNA score 18/100 — Weak. P/E of 140.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹50.42
-84.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹78.00
-75.4%
√(22.5 × EPS × BVPS)
EPS=2.69, BVPS=100.52 · outside Graham range (P/E 140, P/B 3.2) — asset-light, treat as a rough floor
P/E Fair Value
₹101.41
-68.1%
EPS × 37.7x (sector P/E)
EPS=2.69, Sector P/E=37.7x
EV/EBITDA
₹337.02
+6.1%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=2.15B
Book Value (P/B)
₹24.53
-92.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=100.52, ROE=2.4%, g=3%, r=10%
Reverse DCF
₹317.65
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 31.5% | Historical: 0%
Margin of Safety
₹57.46
-81.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=76.61, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.